Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A multicenter, randomized, open-label, phase 4 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Soohyung | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Choi, Byoung Geol | - |
dc.contributor.author | Kim, Woohyeun | - |
dc.contributor.author | Choi, Woong Gil | - |
dc.contributor.author | Lee, Seung Jin | - |
dc.contributor.author | Lee, Jae Beom | - |
dc.contributor.author | Park, Ji Young | - |
dc.contributor.author | Park, Sang Min | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.contributor.author | Kim, Yong Hoon | - |
dc.contributor.author | Her, Ae-Young | - |
dc.contributor.author | Kim, Min Woong | - |
dc.contributor.author | Chen, Kang-Yin | - |
dc.contributor.author | Kim, Bae Keun | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Seo, Jae-Bin | - |
dc.contributor.author | Ahn, Jihun | - |
dc.contributor.author | Choi, Se Yeon | - |
dc.contributor.author | Byun, Jae Kyeong | - |
dc.contributor.author | Cha, Jin Ah | - |
dc.contributor.author | Hyun, Su Jin | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.date.accessioned | 2023-12-14T06:31:18Z | - |
dc.date.available | 2023-12-14T06:31:18Z | - |
dc.date.issued | 2023-11 | - |
dc.identifier.issn | 0002-8703 | - |
dc.identifier.issn | 1097-6744 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25490 | - |
dc.description.abstract | Background Previous studies reported that compared to conventional dual antiplatelet therapy (DAT; aspirin + clopi-dogrel), triple antiplatelet therapy (TAT), involving the addition of cilostazol to DAT, had better clinical outcomes in patients with ST-elevation myocardial infarction (STEMI). However, the optimal duration of TAT is yet to be determined.Methods In total, 985 patients with STEMI who underwent primary percutaneous coronary intervention (PCI) with drug -eluting stents (DESs) were prospectively enrolled in 15 PCI centers in South Korea and China. We randomly assigned patients into 3 groups: DAT (aspirin and clopidogrel for 12 months), TAT 1M (aspirin, clopidogrel, and cilostazol for 1 month), and TAT 6M (aspirin, clopidogrel, and cilostazol for 6 months). The primary endpoint was 1-year major adverse cardiovascular events (MACEs), defined as a composite of all-cause death, recurrent myocardial infarction, stroke, or repeat revascularization.Results The primary endpoint did not differ among the 3 groups (8.8% in DAT, 11.0% in TAT 1M, and 11.6% in TAT 6M; hazard ratio for TAT 1M vs DAT, 1.302; 95% confidence interval [CI], 0.792-2.141; P = .297; hazard ratio for TAT 6M vs DAT, 1.358; 95% CI, 0.829-2.225; P = .225). With respect to in-hospital outcomes, more bleeding events occurred in the TAT group than in the DAT group (1.3% vs 4.7% vs 2.6%, P = .029), with no significant differences in major bleeding events. Additionally, the TAT group had a higher incidence of headaches (0% vs 1.6% vs 2.6%, P = .020).Conclusions The addition of cilostazol to DAT did not reduce the incidence of 1-year MACEs compared with DAT alone. Instead, it may be associated with an increased risk of drug intolerance and side effects, including in-hospital bleeding and headaches. (Am Heart J 2023;265:11-21.) | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | MOSBY-ELSEVIER | - |
dc.title | Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A multicenter, randomized, open-label, phase 4 trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.ahj.2023.06.015 | - |
dc.identifier.scopusid | 2-s2.0-85164403945 | - |
dc.identifier.wosid | 001045255300001 | - |
dc.identifier.bibliographicCitation | AMERICAN HEART JOURNAL, v.265, pp 11 - 21 | - |
dc.citation.title | AMERICAN HEART JOURNAL | - |
dc.citation.volume | 265 | - |
dc.citation.startPage | 11 | - |
dc.citation.endPage | 21 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | ELUTING STENT IMPLANTATION | - |
dc.subject.keywordPlus | REDUCES LATE RESTENOSIS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | TICAGRELOR | - |
dc.subject.keywordPlus | PRASUGREL | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | IMPACT | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.